ArticlesAzithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial
Introduction
Bronchiectasis is a disorder characterised by neutrophilic airway inflammation, chronic bacterial infection, and recurrent pulmonary exacerbations.1 Patients with bronchiectasis can have a disabling cough with production of large amounts of sputum, progressive decline in lung function,2 impaired quality of life,3, 4 and increased mortality.5, 6 Exacerbations occur at rates of 1·5–6·5 per patient per year,7, 8 and are associated with an increased risk of admission and readmission to hospital, and high health-care costs.9
The prevalence of bronchiectasis in most adult populations worldwide is unknown. With the widespread availability of modern diagnostic techniques such as high-resolution CT scanning, bronchiectasis is increasingly being recognised. In the USA, the number of bronchiectasis-associated admissions increased by 2–3% per year between 1993 and 2006, and the mean annual rate of admission in this period was 16·5 per 100 000 people.9 A further study10 showed that the prevalence of bronchiectasis increased by 8·7% per year between 2000 and 2007.
Few evidence-based treatments are available for the prevention and management of exacerbations and more are urgently needed.11 Macrolide antibiotics have anti-inflammatory and immunomodulatory properties in addition to their antibacterial properties.12 In the Effectiveness of Macrolides in patients with BRonchiectasis using Azithromycin to Control Exacerbations (EMBRACE) trial, we tested whether azithromycin decreases the frequency of exacerbations, increases lung function, and improves health-related quality of life in patients with non-cystic fibrosis bronchiectasis.
Section snippets
Study design and participants
We undertook a randomised, double-blind, placebo-controlled trial at three centres in New Zealand between Feb 12, 2008, and Oct 15, 2009. Patients were eligible for inclusion in the study when they were 18 years or older, had had at least one pulmonary exacerbation requiring antibiotic treatment in the past year, and had a diagnosis of bronchiectasis defined by high-resolution CT scan. All CT scans were reviewed centrally by one respiratory radiologist (DM) to verify the diagnosis of
Results
141 patients underwent randomisation and all patients received at least one dose of the assigned treatment (figure 1). Table 1 shows baseline characteristics and concomitant use of respiratory medications. Fewer patients in the azithromycin group than in the placebo group withdrew from the study prematurely (figure 1). We established from pill counts that patients adhered 97·9% of the time in the azithromycin group and 98·3% of the time in the placebo group.
42 event-based exacerbations were
Discussion
We have shown that azithromycin treatment for 6 months in patients with non-cystic fibrosis bronchiectasis significantly decreases the rate of event-based exacerbations and increases the time to the first event-based exacerbation compared with placebo. These benefits persisted for 6 months after completion of treatment.
Randomised trials of other macrolides for treatment of non-cystic fibrosis bronchiectasis16, 17, 18 have previously been undertaken (panel). Five studies in patients with cystic
References (37)
- et al.
Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis
Chest
(2007) - et al.
Quality-of-life determinants in patients with clinically stable bronchiectasis
Chest
(2005) - et al.
Trends in bronchiectasis mortality in England and Wales
Respir Med
(2010) - et al.
Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I
Chest
(1998) - et al.
Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993–2006
Chest
(2010) - et al.
Bronchiectasis: CT/clinical correlations
Semin Ultrasound CT MR
(1995) - et al.
Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial
Lancet
(2002) - et al.
Characterisation of the onset and presenting clinical features of adult bronchiectasis
Respir Med
(2006) - et al.
Airway inflammation in cystic fibrosis
Chest
(2008) - et al.
Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study
Lancet
(2007)
Bronchiectasis
N Engl J Med
Validation of the St. George's Respiratory Questionnaire in bronchiectasis
Am J Respir Crit Care Med
Mortality in bronchiectasis: a long-term study assessing the factors influencing survival
Eur Respir J
British Thoracic Society guideline for non-CF bronchiectasis
Thorax
Trends in bronchiectasis among medicare beneficiaries in the United States, 2000–2007
Chest
Exacerbations in cystic fibrosis: 4—non-cystic fibrosis bronchiectasis
Thorax
Mechanisms of action and clinical application of macrolides as immunomodulatory medications
Clin Microbiol Rev
ATS statement: guidelines for the six-minute walk test
Am J Respir Crit Care Med
Cited by (472)
Facile synthesis of silver selenide anchored on β-cd/reduced graphene oxide hybrid composites for electrochemical sensing of azithromycin in biological and environmental samples
2024, Journal of the Taiwan Institute of Chemical EngineersInhaled dry powder liposomal azithromycin for treatment of chronic lower respiratory tract infection
2024, International Journal of PharmaceuticsAzithromycin reduces hemoglobin-induced innate neuroimmune activation
2024, Experimental NeurologyCommon Variable Immunodeficiency
2024, Medical Clinics of North AmericaInvestigation and Management of Bronchiectasis in Nontuberculous Mycobacterial Pulmonary Disease
2023, Clinics in Chest MedicineMedications and Monitoring in Treatment of Nontuberculous Mycobacterial Pulmonary Disease
2023, Clinics in Chest Medicine